BioPharma Resources

Investigational drug · Phase 3

MK-2140

Also called: Zilovertamab Vedotin, VLS-101

Not approved by FDA. In 9 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Diffuse Large B-Cell Lymphoma, Lymphoma, Large B-Cell, Diffuse, B-cell Acute Lymphoblastic Leukemia.

Phase 3

Last checked: Nov 19, 2026Latest source record: Nov 13, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 3

Industry-sponsored trials

Phase 2 and 3 trials

9

8 still active

All registered trials

11

Any phase or sponsor naming "MK-2140"

First trial start

2022

Jan 8, 2022

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "MK-2140", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Diffuse Large B-Cell Lymphoma
  • Lymphoma, Large B-Cell, Diffuse
  • B-cell Acute Lymphoblastic Leukemia
  • Diffuse Large B-cell Lymphoma
  • Burkitt Lymphoma
  • Neuroblastoma
  • Ewing Sarcoma
  • Lymphoma, Large B-Cell, Diffuse (DLBCL)
  • Chronic Lymphocytic Leukemia
  • Mantle Cell Lymphoma

Approved drugs for the same conditions: Sarcoma · Chronic lymphocytic leukemia · Acute lymphoblastic leukemia · Lymphoma (non-Hodgkin) · Oncology · Hematology and blood cancers

Largest trials

Live from ClinicalTrials.gov: studies naming "MK-2140" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 12 on PubMed

Also in development for Diffuse Large B-Cell Lymphoma

  • SintilimabIBI308Phase 321 trials

    Innovent Biologics (Suzhou) Co. Ltd. · Hepatocellular Carcinoma, Solid Tumor, HCC - Hepatocellular Carcinoma

  • BirelentinibDZD8586Phase 37 trials

    Dizal Pharmaceuticals · Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Diffuse Large B-Cell Lymphoma, Immune Thrombocytopenia (ITP)

  • MK-1045CN-201Phase 36 trials

    Merck & Co. · Lymphoma, Large B-Cell, Diffuse, Lymphoma, Non-Hodgkin, Lymphoma, Follicular

  • RituxumabPhase 32 trials

    Roche (Genentech) · Diffuse Large B-cell Lymphoma, DLBCL - Diffuse Large B Cell Lymphoma

  • BL-M08D1Phase 26 trials

    Sichuan Baili Pharmaceutical Co., Ltd. · Solid Tumors, Gastrointestinal Tumors, Diffuse Large B-Cell Lymphoma

  • GNC-038Phase 24 trials

    Sichuan Baili Pharmaceutical Co., Ltd. · Non-hodgkin's Lymphoma, Primary Central Nervous System Lymphoma, Secondary Central Nervous System Lymphoma

  • and oxaliplatinPhase 22 trials

    Suzhou Suncadia Biopharmaceuticals Co., Ltd. · HER2 Expression Gastric Cancer/Gastroesophageal Junction Adenocarcinoma, Diffuse Large B-Cell Lymphoma, Follicular Lymphoma

  • and prednisonePhase 22 trials

    Genmab · Follicular Lymphoma, Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Merck & Co..

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.